Drug intelligence / Profile preview

PTX-10-3

Development stage: Preclinical
Lead developer: PharmatrophiX
Modality: Small Molecules

Overview

PTX-10-3 is a preclinical-stage small molecule developed by PharmatrophiX, designed to target the neurotrophin receptors Tropomyosin receptor kinase B (TrkB) and Tropomyosin receptor kinase C (TrkC). These receptors play critical roles in neuronal survival, differentiation, and synaptic plasticity. By targeting both TrkB and TrkC, PTX-10-3 is intended to address the complex pathology of neurodegenerative diseases, potentially offering a broader therapeutic effect than single-receptor modulators. The compound is currently in the early stages of development for neurodegeneration.

Targets

NTRK3 (Tropomyosin receptor kinase C)NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on PTX-10-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-10-3.

Explore the full profile